Literature DB >> 2101466

Immunity induced by live attenuated Salmonella vaccines.

C E Hormaeche1, H S Joysey, L Desilva, M Izhar, B A Stocker.   

Abstract

Studies on the degree and specificity of protection conferred by immunization with aroA salmonella live vaccines in BALB/c mice are described. Animals were immunized i.v. and challenged orally 3 months later to ensure that the vaccine had been cleared from the tissues. Vaccination with Salmonella typhimurium aroA SL3261 conferred very good protection against virulent S. typhimurium C5 (over 10,000 x LD50). The specificity of cross protection was studied using S. typhimurium, Salmonella enteritidis and Salmonella dublin for vaccination and challenge, including challenge with variants of S. typhimurium and S. enteritidis of similar virulence which differed in the main LPS (lipopolysaccharide) antigen (0-4 or 0-9). S. typhimurium SL3261 gave very good protection against S. typhimurium C5 (0-4), but no protection against S. enteritidis Se795 (0-9). However, challenge with strains differing in the main 0 antigens showed that, although protection was generally better to strains expressing the same LPS type as the vaccine, specificity of protection was determined more by the background (S. typhimurium or S. enteritidis) of the parent strain used for the challenge than by 0 factors 4 or 9, suggesting that other factors could be involved. The nature of the antigen(s) responsible for protection in this model is unclear, but it would not appear to be the main 0-specific antigen. An S. enteritidis Se795 aroA vaccine was far less effective than S. typhimurium SL3261; it conferred good protection against the homologous wild type at 2 weeks post-vaccination, but far less at three months (approx 10-200 x LD50). This was unexpected, as the persistence of the S. enteritidis vaccine in the liver and spleen was similar to that of S. typhimurium SL3261, and the S. enteritidis and S. typhimurium challenge strains were of similar virulence. An S. dublin aroA vaccine conferred similar protection against wild type S. dublin (approx 300 x LD50).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2101466     DOI: 10.1016/0923-2508(90)90107-2

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  13 in total

1.  A novel relationship between O-antigen variation, matrix formation, and invasiveness of Salmonella enteritidis.

Authors:  J Guard-Petter; L H Keller; M M Rahman; R W Carlson; S Silvers
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

2.  Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains.

Authors:  Sharon M Tennant; Jin-Yuan Wang; James E Galen; Raphael Simon; Marcela F Pasetti; Orit Gat; Myron M Levine
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

3.  Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.

Authors:  Marcio O Lásaro; Wilson B Luiz; Maria E Sbrogio-Almeida; Lucilia S Nishimura; Beatriz E C Guth; Luis C S Ferreira
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.

Authors:  Christine Hale; Frances Bowe; Derek Pickard; Simon Clare; Jean-Francois Haeuw; Ultan Powers; Nathalie Menager; Pietro Mastroeni; Gordon Dougan
Journal:  Vaccine       Date:  2006-03-20       Impact factor: 3.641

5.  Lipopolysaccharide-specific but not anti-flagellar immunoglobulin A monoclonal antibodies prevent Salmonella enterica serotype enteritidis invasion and replication within HEp-2 cell monolayers.

Authors:  Ianko D Iankov; Dragomir P Petrov; Ivan V Mladenov; Iana H Haralambieva; Ivan G Mitov
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Cutting Edge: Lymphotoxin Signaling Is Essential for Clearance of Salmonella from the Gut Lumen and Generation of Anti-Salmonella Protective Immunity.

Authors:  Joanna A Wroblewska; Yuan Zhang; Haidong Tang; Xiaohuan Guo; Cathryn Nagler; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-12-02       Impact factor: 5.422

7.  Characterization and development of T-Cell immune responses in B-cell-deficient (Igh-6(-/-)) mice with Salmonella enterica serovar Typhimurium infection.

Authors:  Sanja Ugrinovic; Nathalie Ménager; Natalie Goh; Pietro Mastroeni
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys.

Authors:  J K Kwaga; B J Allan; J V van der Hurk; H Seida; A A Potter
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Salmonella exploits caspase-1 to colonize Peyer's patches in a murine typhoid model.

Authors:  D M Monack; D Hersh; N Ghori; D Bouley; A Zychlinsky; S Falkow
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

10.  Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans.

Authors:  S Khan; S Chatfield; R Stratford; J Bedwell; M Bentley; S Sulsh; R Giemza; S Smith; E Bongard; C A Cosgrove; J Johnson; G Dougan; G E Griffin; J Makin; D J M Lewis
Journal:  Vaccine       Date:  2007-03-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.